3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Multiple Myeloma
5
Breast Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
3
Melanoma
3
Leukemia, Myeloid, Acute
3
Leukemia
3
Carcinoma, Non-Small-Cell Lung
3
Myelodysplastic Syndromes
2
Lymphoma, Mantle-Cell
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hematologic Neoplasms
2
Craniopharyngioma
2
COVID-19
2
Burkitt Lymphoma
2
Arthritis, Rheumatoid
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Unresectable Pancreatic Carcinoma
1
Triple Negative Breast Neoplasms
1
Stroke
1
Sarcoma
1
Respiratory Tract Infections
1
Recurrence
1
Pulmonary Disease, Chronic Obstructive
1
Prostatic Neoplasms
1
Pleural Effusion, Malignant
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Interventions
Gemcitabine
406
Oxaliplatin
131
Fluorouracil
125
130-nm albumin-bound paclitaxel
108
Capecitabine
100
Albumin-Bound Paclitaxel
90
Leucovorin
88
Irinotecan
87
Radiotherapy
76
Radiosurgery
64
Taxes
63
Cisplatin
56
Erlotinib Hydrochloride
44
Drug Therapy
42
folfirinox
40
Magnetic Resonance Spectroscopy
39
pembrolizumab
35
Blood Specimen Collection
33
S 1 (combination)
31
Pancreaticoduodenectomy
31
Docetaxel
31
Nivolumab
30
Bevacizumab
30
Biopsy
26
Surgical Procedures, Operative
25
Cyclophosphamide
25
irinotecan sucrosofate
24
Specimen Handling
24
Radiation
22
Standard of Care
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pancreatic Neoplasms
×
tocilizumab
×
Clear all
NCT04258150
2022-03-31
TRIPPLE-R
Herlev Hospital
Phase 2
Terminated
26 enrolled